Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Interest Receivables (2024 - 2025)

Historic Change in Interest Receivables for SAB Biotherapeutics (SABS) over the last 2 years, with Q3 2025 value amounting to $559954.0.

  • SAB Biotherapeutics' Change in Interest Receivables rose 53788.48% to $559954.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $462907.0, marking a year-over-year change of. This contributed to the annual value of $54955.0 for FY2024, which is N/A changed from last year.
  • Per SAB Biotherapeutics' latest filing, its Change in Interest Receivables stood at $559954.0 for Q3 2025, which was up 53788.48% from -$21386.0 recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Change in Interest Receivables high stood at $559954.0 for Q3 2025, and its period low was -$127877.0 during Q3 2024.